Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

CAN (MB): Health Canada issues license and oil sales authorization

Delta 9 Cannabis received its renewal license from Health Canada for a term of three years. This license authorizes Delta 9 to cultivate, process and sell cannabis from its Winnipeg production facility. The Company has also provided an update on cannabis oils sales, cannabis pre-rolls sales, and new product development.

Health Canada License Renewal and Oils Sales Authorization
The Company, through its subsidiary, Delta 9 Bio-Tech Inc., has received its renewed Standard Cultivation and Standard Processing license for cannabis from Health Canada. The Company has fulfilled Health Canada's rigorous specifications, and successfully passed all inspections.

"Delta 9 employees have worked hard to meet the requirements within Health Canada's strictly regulated licensing environment. It speaks to the professionalism of our team that it has maintained the high standards of safety, quality and security in accordance with Health Canada's regulations for licensed producers," said John Arbuthnot, Chief Executive Officer of Delta 9.

The Company has also received approval from Health Canada for sales of cannabis oil products. According to them, the Company has already completed production of several initial batches of its "Odyssey" and "Oasis" lines of ingestible oils and will proceed with sales of these products in the medical and recreational use cannabis markets.

In June this year the Company launched its "Bliss" line of pre-rolled cannabis products, which consist of blended cannabis flower, rolled in a cigarette format for sale in the medical and recreational use cannabis markets. To date the Company has produced and sold over 75,000 cannabis pre-rolls.

"It is management's belief that these products will become an increasingly important component of the medical and recreational use cannabis markets in the future," said John Arbuthnot, Chief Executive Officer of Delta 9. 

Products for Future Development

Nanosphere Evolve Products
Delta 9 has acquired an exclusive license in Canada to manufacture and sell products made with the patented technology of Nanosphere Health Sciences for the delivery of cannabinoids via nanoparticle technology. The two companies are in the process of developing the first product for Canada; an intraoral cannabis oil containing cannabinoid nanoparticles.

"The NanoSphere delivery system for cannabis works by nano-encapsulating active ingredients in phospholipid membranes for transportation through the skin and mucosa into the bloodstream within minutes," the team with the company explains. "Cannabis applications of the technology include transdermal viscous gels, intranasal products and intraoral products, all of which provide rapid results, precise dosages and high bioavailability. The NanoSphere delivery system of cannabis can eliminate the need for inhalation or ingestion of cannabis, offering users a potentially safer and more effective method of consumption."

Oils, Extracts, and Derivative Products
According to them, the Company continues to develop and expand its in-house oils production capacity and is working with partners regarding its strategy for new cannabis extracts and derivative products once the federal government finalizes its expanded extract regulations, which are expected to become effective in 2019.

For more information:
Delta 9 Cannabis
[email protected]    

Publication date: